首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   363篇
  免费   25篇
  国内免费   2篇
耳鼻咽喉   12篇
儿科学   9篇
妇产科学   2篇
基础医学   57篇
口腔科学   6篇
临床医学   10篇
内科学   130篇
皮肤病学   2篇
神经病学   5篇
特种医学   2篇
外科学   7篇
综合类   16篇
预防医学   22篇
药学   52篇
中国医学   31篇
肿瘤学   27篇
  2023年   3篇
  2022年   6篇
  2021年   17篇
  2020年   5篇
  2019年   18篇
  2018年   18篇
  2017年   30篇
  2016年   6篇
  2015年   10篇
  2014年   22篇
  2013年   28篇
  2012年   21篇
  2011年   22篇
  2010年   17篇
  2009年   26篇
  2008年   31篇
  2007年   25篇
  2006年   25篇
  2005年   18篇
  2004年   10篇
  2003年   11篇
  2002年   5篇
  2001年   4篇
  2000年   3篇
  1999年   2篇
  1998年   1篇
  1983年   2篇
  1982年   1篇
  1979年   2篇
  1978年   1篇
排序方式: 共有390条查询结果,搜索用时 15 毫秒
71.
目的:探究薏苡附子败酱散(Yiyi Fuzi Baijiang San,YYFZBJS)联合电针(electroacupuncture,EA)对AOM/DSS模型小鼠炎症相关性结直肠癌(colitis-associated colorectal cancer,CAC)的防治作用及对结直肠癌上皮间质转化(epithelial-mesenchymal transition,EMT)相关蛋白表达情况的影响。方法:建立AOM/DSS诱导的CAC小鼠模型,将40只小鼠随机分为模型组、针药结合组、薏苡附子败酱散组、电针组和阿司匹林组,于实验第2周开始干预治疗,治疗过程中记录各组小鼠一般情况,统计体质量变化、疾病活动指数(disease activity index,DAI)评分及生存情况,于实验末比较各组小鼠结直肠长度、成瘤数量及肿瘤大小,通过HE染色观察结直肠组织及肿瘤组织的病理变化,免疫组织化学染色观察结直肠肿瘤Ki-67、PCNA、p-NF-κB、NF-κB、E-cadherin、ZO-1、Occludin、Vimentin和N-cadherin蛋白的表达。结果:与模型组相比,针药结合组小鼠体质量显著升高(P<0.05),DAI分值降低(P<0.05),生存率为87.5%,结直肠长度显著增加(P<0.01),直径小于2 mm的肿瘤数量减少(P<0.05),直径介于2~4 mm之间和大于4 mm的肿瘤数量显著减少(P<0.01),总成瘤数量明显下降(P<0.01),结直肠形态明显改善;肿瘤组织病理评分降低(P<0.01),肿瘤组织中Ki-67、PCNA、p-NF-κB、NF-κB、Vimentin和N-cadherin蛋白表达量降低(P<0.01),E-cadherin、ZO-1和Occludin蛋白表达量升高(P<0.05)。结论:薏苡附子败酱散联合电针对AOM/DSS模型小鼠的CAC发生发展有防治作用,其机制可能与下调NF-κB信号通路,减缓EMT进程有关。  相似文献   
72.
Estrogens regulate growth and development through the action of two distinct estrogen receptors (ERs), ERα and ERβ, which mediate proliferation and differentiation of cells. For decades, ERα mediated estrogen signaling has been therapeutically targeted to treat breast cancer, most notably with the selective estrogen receptor modulator (SERM) tamoxifen. Selectively targeting ERs occurs at two levels: tissue selectivity and receptor subtype selectivity. SERMs have been developed with emphasis on tissue selectivity to target ER signaling for breast cancer treatment. Additionally, new approaches to selectively target the action of ERα going beyond ligand-dependent activity are under current investigation. As evidence of the anti-proliferative role of ERβ accumulates, selectively targeting ERβ is an attractive approach for designing new cancer therapies with the emphasis shifted to designing ligands with subtype selectivity. This review will present the mechanistic and structural features of ERs that determine tissue and subtype selectivity with an emphasis on current approaches to selectively target ERα and ERβ for cancer treatment.  相似文献   
73.
Inflammatory bowel disease (IBD) is characterized by repeated chronic inflammation of the gastrointestinal tract. We have used the complementary model of colonic inflammation to examine the roles of peroxisome proliferator-activated receptor α (PPARα) in colonic inflammation and thus its possible role in IBD. We characterized an innate immune-mediated model of colitis induced by dextran sulfate sodium (DSS). Mice with DSS-induced colitis were injected with Wy-14643 (2 mg/kg) as a PPARα agonist every day from day 0 to day 5. We show that mice given Wy-14643 were less susceptible to experimental acute colitis induced by DSS, and this decreased susceptibility was correlated with decreased production of IFNγ, IL-1β, IL-6, and TNF-α. Our findings suggest that PPARα has a role in controlling colonic inflammation and mucosal tissue homeostasis.  相似文献   
74.
Chronic inflammation associated with viral and bacterial infections of the gastrointestinal tract (GI) and liver renders these organs susceptible to tumour development. There is also a growing body of evidence demonstrating that chemical and physical insults promote GI cancers by inducing inflammation. For example, excessive alcohol consumption and tobacco smoking induces inflammation and gastrointestinal carcinogenesis. Likewise, drinking hot beverages and intentional or accidental exposure to toxic substances leads to inflammation and GI cancer formation. However, further work needs to be undertaken using animal models to separate the direct carcinogenic effects of physical and chemical insults from the indirect effects of these insults to promote tumor formation through tissue inflammation.  相似文献   
75.
Encouraged by our earlier results of promising therapeutic effect of filarial recombinant proteins BmALT2, BmCys and WbL2 individually in the mouse model of acute ulcerative colitis, in this study, these proteins have been explored individually and in different combinations for their therapeutic potential in dextran sulphate sodium (DSS)‐induced chronic colitis mice. These mice, treated with filarial proteins, showed reduced disease parameters including body weight loss, disease activity index, macroscopic and histopathological scores of colon and myeloperoxidase activity in colonic mucosa. Among various treatment schemes, rBmALT2 + rBmCys which showed most pronounced therapeutic implication was found to downregulate the mRNA expressions of IFN‐γ and TNF‐α and upregulate IL‐10 and TGF‐β expression in the splenocytes. Also, increase in level of IgG1 and IgG2a isotypes in the sera of rBmALT2 + rBmCys‐treated colitis mice was noted. Activated NF‐κB level was found to be reduced in the colon of treated colitis mice compared to untreated one. In conclusion, filarial proteins in combination have been shown to improve the clinicopathologic status of chronic colitis through suppression of pro‐inflammatory immune response most possibly in NF‐κB‐dependent manner. We propose this therapeutic strategy to be tested further to be considered as an effective option in chronic colitis.  相似文献   
76.
77.
78.

Objective

To assess whether preterm birth and low birth weight were associated with single and recurrent episodes of acute otitis media (AOM) the first 18 months of life.

Methods

The study population consisted of 33,192 children in the Norwegian Mother and Child Cohort, conducted at the Norwegian Institute of Public Health. The majority of all pregnant women in Norway were invited to participate and the response rate was 44%. Participating women received questionnaires during pregnancy and when the child was 6 and 18 months. Main outcome measures were maternal reports of AOM at ages 6, 11 and 18 months. Information on birth weight and gestational age was obtained from the Medical Birth Registry of Norway. Regression analyses were performed controlling for a variety of potential confounders.

Results

Preterm birth was slightly associated with both single and recurrent episodes of AOM the first 18 months of age. The adjusted relative risk (aRR) for having any episode of AOM was 1.37, 95%CI (1.12-1.68) if born before week 33, and the aRR for having recurrent AOM was 1.34, 95%CI (1.01-1.77) if born in weeks 33-36 (reference group: ≥37 weeks). A corresponding tendency was not found for low birth weight.

Conclusions

The finding indicates a modest increased risk of having AOM in children born preterm, and preterm birth seems to be more important than low birth weight in determining risk of having AOM in early life.  相似文献   
79.
Abstract Conclusion: This is the first report demonstrating high levels of substance P (SP) that inversely correlate with vasoactive intestinal peptide (VIP) levels in middle ear effusions (MEEs) of patients with otitis media with effusion (OME). Increased SP and decreased VIP levels might play a role in the pathogenesis of chronic OME. Objective: The etiology of OME is multifactorial, and neurogenic inflammation may play a significant role. SP and VIP levels were not evaluated previously in MEEs of children with OME. Methods: Fifty patients aged 2-12 years (mean age 5.24 ± 2.64) were included in the study. MEEs were classified as mucoid or serous based on the gross appearance. SP and VIP levels were determined using ELISA. Results: High levels of SP were detected in MEEs. In addition SP levels were significantly higher in serous samples (2910.55 ± 307.96 vs 2218.55 ± 262.30 pg/ml). There were also age-dependent changes, such that SP levels were significantly higher in children aged 2-3 years compared with those who were 4-5 and 6-12 years old. VIP levels were undetectable in 30% of patients and the mean level of VIP was 50.91 ± 16.01 pg/ml in serous middle ear effusions and 54.86 ± 15.91 pg/ml in mucoid MEEs.  相似文献   
80.
《Acta oto-laryngologica》2012,132(5):480-485
Conclusions. Single and repeated episodes of acute otitis media (AOM) in 10-year-old children were associated with reported allergic disease. Further, skin prick test (SPT)-negative children with reported asthma and allergic rhinoconjunctivitis had increased risk of AOM. We suggest that optimal treatment of allergic symptoms may have an effect on AOM in school children. Objective. The objective of the study was to estimate associations between AOM, allergic diseases and SPT positivity in 10-year-old children. Materials and methods. Population-based cross-sectional study of 3406 10-year-old children living in Oslo. Main outcome measures were questionnaire-based information on AOM and reported physician-diagnosed allergic diseases with symptoms during the last year. In addition, 2657 children were skin prick tested. Logistic regression analyses were performed to estimate associations and control for potential confounders. Results. One or more episodes of AOM were present in 13.8% (n=470) of the children; 9.7% (n=331) had single episodes, while 4.1% (n=139) had two or more infections. We found a statistically significant association between AOM and reported allergic diseases, strongest for AOM and asthma with odds ratio 2.7 (95% confidence interval 1.8–4.0) and 2.3 (95% confidence interval 1.3–4.3) for single and two or more episodes of AOM, respectively. The risk for AOM was increased in asthmatic SPT-negative children compared with asthmatic SPT-positive children, the odds ratios were 3.0 (1.7–5.4) and 1.5 (0.8–2.8), respectively. The same tendency was found for allergic rhinoconjunctivitis.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号